Press Releases

News

E-Cigarette Users Have Lower Exposure to Toxicants — As Long As They Don’t Smoke Combustible Cigarettes Too

The largest study to date to compare exposure to toxicants among users of electronic cigarettes, smokers and nonsmokers has been completed, suggesting possible benefits for smokers who switch completely to electronic cigarettes. The research team, led by Maciej Goniewicz, PhD, PharmD, and Andrew Hyland, PhD, of Roswell Park Comprehensive Cancer Center in collaboration with scientists from Westat, the National Institute on Drug Abuse (NIDA), the U.S. Food and Drug Administration (FDA) and other academic centers, saw clear evidence that e-cigarette users, while exposed to more toxicants than people who do not use any form of tobacco, evidence significantly lower levels of toxicants than those who smoke cigarettes.
Rikki Cannioto in Rehab Center
News

Exercise Significantly Cuts the Risk of Death from Cancer

New research out of Roswell Park Comprehensive Cancer Center shows that cancer patients who exercise regularly both before and after their diagnosis are significantly more likely to survive than those who are sedentary, adding to the growing body of evidence that physical activity is an important part of a cancer prevention and treatment strategy. The results were published in a recent issue of the journal Cancer Causes & Control.
News

Opioid Prescriptions Can Be Drastically Reduced After Surgery with No Increase in Pain, Study Shows

Pain after surgery can be effectively managed with minimal or no opioids, according to research conducted at Roswell Park Comprehensive Cancer Center and published today in JAMA Network Open. A two-year study by a multidisciplinary team of surgeons and other cancer specialists shows that the amount of opioid medications prescribed after surgery can be drastically reduced without negatively affecting pain scores, postoperative complications or patient requests for additional opioids, demonstrating that alternative approaches to pain management can be both safe and highly effective.

News

Roswell Park’s Dr. Igor Puzanov Honored for His Many Contributions to Melanoma Research

Roswell Park Comprehensive Center’s Igor Puzanov, MD, MSci, FACP, was honored for his “outstanding and lifelong contributions to melanoma research” during the just-concluded Melanoma and Immunotherapy Bridge research meeting in Naples, Italy. Dr. Puzanov, who is Chief of Melanoma and Director of the Early Phase Clinical Trials Program at Roswell Park, received the award from Italy’s Fondazione Melanoma, or Melanoma Foundation.
News

Roswell Park Hematologists Bring Expertise in Cellular Therapies, Genomic Testing and Rare Lymphoma to ASH 2018

Roswell Park Comprehensive Cancer Center hematology experts from many disciplines and subspecialties were invited to present new research at the American Society of Hematology (ASH) 60th Annual Meeting, which begins today and continues through Tuesday, Dec. 4, in San Diego, California. The dozens of research projects they will highlight include new research on management of aggressive and rare lymphomas, approaches for optimizing cellular therapies such as blood and marrow transplant, and decision-making around genomic testing for patients with acute myeloid leukemia.
News

Brain Cancer Immunotherapy SurVaxM Extends Survival, Even in Hard-to-Treat Patients

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented earlier this month at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.
News

Brain Cancer Immunotherapy SurVaxM Extends Survival, Even in Hard-to-Treat Patients

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented Friday at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.